Browsing by Author "Moore, Keith"

Now showing 1 - 2 of 2
  • Thumbnail Image
    CIRED: A brief history of the Center for International Research, Education, and Development at Virginia Tech
    Moore, Keith (Virginia Tech. Center for International Research, Education, and Development, 2020)
    This publication provides a photographic, yet reflective look at the people, programs, and partners that have defined CIRED as we know it today.
  • Thumbnail Image
    Impact of the controlled release of a connexin 43 peptide on corneal wound closure in an STZ model of type I diabetes.
    Moore, Keith; Ghatnekar, Gautam S.; Gourdie, Robert G.; Potts, Jay D. (2014)
    The alpha-carboxy terminus 1 (αCT1) peptide is a synthetically produced mimetic modified from the DDLEI C-terminus sequence of connexin 43 (Cx43). Previous research using various wound healing models have found promising therapeutic effects when applying the drug, resulting in increased wound healing rates and reduced scarring. Previous data suggested a rapid metabolism rate in vitro, creating an interest in long term release. Using a streptozotocin (STZ) type I diabetic rat model with a surgically induced corneal injury, we delivered αCT1 both directly, in a pluronic gel solution, and in a sustained system, using polymeric alginate-poly-l-ornithine (A-PLO) microcapsules (MC). Fluorescent staining of wound area over a 5 day period indicated a significant increase in wound closure rates for both αCT1 and αCT1 MC treated groups, withαCT1 MC groups showing the most rapid wound closure overall. Analysis of inflammatory reaction to the treatment groups indicated significantly lower levels of both Interferon Inducible T-Cell Alpha Chemoattractant (ITAC) and Tumor Necrosis Factor Alpha (TNFα) markers using confocal quantification and ELISA assays. Additional analysis examining genes selected from the EMT pathway using RT-PCR and Western blotting suggested αCT1 modification of Transforming Growth Factor Beta 2 (TGFβ2), Keratin 8 (Krt8), Estrogen Receptor 1 (Esr1), and Glucose Transporter 4 (Glut4) over a 14 day period. Combined, this data indicated a possible suppression of the inflammatory response by αCT1, leading to increased wound healing rates.